Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era
- 1 April 2005
- journal article
- research article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 16 (3) , 255-262
- https://doi.org/10.1007/s10552-004-3484-8
Abstract
Objective The insulin-like growth factor (IGF) axis is thought to contribute to the growth and progression of prostate cancer. Some prospective studies support a direct association between IGF-1 and prostate cancer, in particular advanced disease, whereas both inverse and direct associations with prostate cancer have been reported for insulin-like growth factor binding protein-3 (IGFBP-3), the major IGF-1 binding protein in circulation. We prospectively investigated the associations of plasma IGF-1 and IGFBP-3 concentrations with prostate cancer detected in the PSA era. Methods: We identified 462 prostate cancer cases diagnosed after providing a blood specimen in 1993, but before January 1998 among men in the Health Professionals Follow-up Study. Controls were 462 age-matched men without prostate cancer who had had a PSA test after providing a blood specimen. We measured plasma concentrations of IGF-1 and IGFBP-3 by ELISA. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) of prostate cancer. Results: Men with higher concentrations of IGF-1 (comparing extreme quartiles OR=1.37, 95% CI 0.92–2.03, p-trend=0.05) and IGFBP-3 (OR=1.62, 95% CI 1.07–2.46, p-trend=0.08) had a higher risk of prostate cancer. After mutual statistical adjustment, these associations were attenuated for both IGF-1 (OR=1.17, 95% CI 0.69–1.99, p-trend=0.29) and IGFBP-3 (OR=1.40, 95% CI 0.80–2.44, p-trend=0.56). We found no significant association of IGF-1 with regionally invasive or metastatic (≥T3b, N1, or M1) prostate cancer, although the number of these cases was small (n=42). Conclusions: Our findings for IGF-1 and prostate cancer diagnosed in the PSA era are similar to most previous studies, albeit weaker in magnitude. Our suggestive positive findings for IGFBP-3 are similar to some studies, but in direct contrast to others.Keywords
This publication has 15 references indexed in Scilit:
- High Levels of Circulating Insulin-Like Growth Factor-I Increase Prostate Cancer Risk: A Prospective Study in a Population-Based Nonscreened CohortJournal of Clinical Oncology, 2004
- Body Mass Index and Risk of Prostate Cancer in U.S. Health ProfessionalsJNCI Journal of the National Cancer Institute, 2003
- Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2001
- Plasma Insulin-Like Growth Factor-I, Insulin-Like Growth Factor-Binding Proteins, and Prostate Cancer Risk: a Prospective StudyJNCI Journal of the National Cancer Institute, 2000
- Serum Levels of Insulin-Like Growth Factor I (IGF-I), IGF-II, IGF-Binding Protein-3, and Prostate-Specific Antigen as Predictors of Clinical Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2000
- Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-α Regulate Transcriptional Signaling and ApoptosisJournal of Biological Chemistry, 2000
- Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasiaBritish Journal of Cancer, 1997
- Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent MechanismJournal of Biological Chemistry, 1997
- The IGF Axis in the ProstateHormone and Metabolic Research, 1994
- Insulin-Like Growth Factors (IGFs), IGF Receptors, and IGF-Binding Proteins in Primary Cultures of Prostate Epithelial Cells*Journal of Clinical Endocrinology & Metabolism, 1991